Psoriasis Drugs Market Size, Share, Industry Trends and Forecast to 2033
This market report provides a comprehensive analysis of the Psoriasis Drugs industry, examining key trends, market size, and CAGR from 2023 to 2033. Insights include market segmentation, regional analysis, and forecasts that will guide stakeholders in informed decision-making.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $10.50 Billion |
| CAGR (2023-2033) | 5.2% |
| 2033 Market Size | $17.63 Billion |
| Top Companies | AbbVie, Amgen, Novartis, Johnson & Johnson, GSK |
| Last Modified Date | 15 Nov 2024 |
Psoriasis Drugs Market Report (2023 - 2033)
Psoriasis Drugs Market Overview
What is the Market Size & CAGR of Psoriasis Drugs market in 2023?
Psoriasis Drugs Industry Analysis
Psoriasis Drugs Market Segmentation and Scope
Request a custom research report for industry.
Psoriasis Drugs Market Analysis Report by Region
Europe Psoriasis Drugs Market Report:
Europe's market is currently valued at 2.89 billion in 2023, projected to grow to 4.84 billion by 2033. The region benefits from advanced healthcare systems and high levels of awareness and treatment accessibility.Asia Pacific Psoriasis Drugs Market Report:
The Asia-Pacific region's psoriasis drugs market is valued at approximately 2.07 billion in 2023, with projections to reach 3.48 billion by 2033. A growing patient population and increased healthcare access are driving this growth, along with rising healthcare expenditures.North America Psoriasis Drugs Market Report:
In North America, the market size stands at 3.74 billion in 2023 and is projected to expand to 6.28 billion by 2033. The dominance of innovative biologics and strong investment in healthcare research play pivotal roles in this region's market growth.South America Psoriasis Drugs Market Report:
The South American market is estimated at 0.35 billion in 2023, anticipated to grow to 0.59 billion by 2033. Market development in this region is influenced by improving healthcare infrastructure and increasing awareness among the population.Middle East & Africa Psoriasis Drugs Market Report:
The Middle East and Africa report a market size of 1.45 billion in 2023, expected to elevate to 2.43 billion by 2033. Factors influencing growth include population health initiatives and improved healthcare policies in the region.Request a custom research report for industry.
Psoriasis Drugs Market Analysis By Drug Class
Global Psoriasis Drugs Market, By Drug Class Market Analysis (2023 - 2033)
Topical treatments account for the largest market share, with a size of 6.82 billion in 2023, expected to reach 11.45 billion by 2033, representing 64.95% market share. Systemic treatments, valued at 2.50 billion in 2023, forecasted to grow to 4.20 billion by 2033, claim a 23.83% share. Phototherapy, while smaller, is critical, with sizes of 1.18 billion in 2023 growing to 1.98 billion, securing the remaining 11.22% share.
Psoriasis Drugs Market Analysis By Stage
Global Psoriasis Drugs Market, By Disease Stage Market Analysis (2023 - 2033)
Mild psoriasis leads the market with a size of 6.82 billion in 2023 and expected growth to 11.45 billion by 2033. Moderate psoriasis accounts for 2.50 billion initially, projected to reach 4.20 billion, while severe psoriasis shows potential for growth from 1.18 billion to 1.98 billion over the same period.
Psoriasis Drugs Market Analysis By Route Of Administration
Global Psoriasis Drugs Market, By Route of Administration Market Analysis (2023 - 2033)
Topical administration remains dominant with a market size of 6.82 billion in 2023, trending to 11.45 billion in 2033. Oral administration is positioned at 2.50 billion, with expectations of reaching 4.20 billion. Injectable options currently have a size of 1.18 billion anticipated to grow to 1.98 billion.
Psoriasis Drugs Market Analysis By End User
Global Psoriasis Drugs Market, By End-User Market Analysis (2023 - 2033)
Hospitals lead the market with a size of 6.82 billion in 2023, predicted to rise to 11.45 billion. Clinics follow at 2.50 billion and expected to grow similarly to home care segments, currently at 1.18 billion, all experiencing extensive growth as treatment models evolve.
Psoriasis Drugs Market Analysis By Region
Global Psoriasis Drugs Market, By Region Market Analysis (2023 - 2033)
Regional analysis indicates North America retains a leading share with a morbidity cost fueling a market size of 4.23 billion in 2023, approaching 7.10 billion by 2033. Europe is confirmed at 2.41 billion, trending upwards to 4.05 billion. The Asia-Pacific region anticipates growth from 1.49 billion to 2.50 billion. The Middle East and Africa, alongside Latin America, maintain growth momentum amidst evolving healthcare systems.
Psoriasis Drugs Market Trends and Future Forecast
Request a custom research report for industry.
Global Market Leaders and Top Companies in Psoriasis Drugs Industry
AbbVie:
Known for its blockbuster drug Humira, AbbVie leads the market in biologics for psoriasis treatment, continually investing in innovative therapies.Amgen:
A major player in the development of systemic therapies, Amgen is recognized for its biologics that specifically target immune mechanisms in plaque psoriasis.Novartis:
With a strong portfolio in dermatological treatments, Novartis focuses on biologics and is committed to expanding treatment options particularly for moderate to severe cases of psoriasis.Johnson & Johnson:
Johnson & Johnson is engaged in the psoriasis drugs market through its effective biologics and is recognized for its research into new dermatology treatments.GSK:
GlaxoSmithKline is notable for its diverse product offerings and ongoing research into new treatment methodologies for psoriasis management.We're grateful to work with incredible clients.
